Skip to main content
. 2022 Apr 15;12(4):e054019. doi: 10.1136/bmjopen-2021-054019

Table 3.

Logistic regression analysis (univariate) for current regimen and outcome variables

Variable VL suppression LTFU
OR (95% CI) P value Adjusted OR (aOR) P value OR (95% CI) P value aOR P value
Current regimen
 First-line regimen 1 1 1 1
 Second-line regimen 0.37 (0.35 to 0.40) <0.001 0.26 (0.23–0.28) <0.001 0.82 (0.78 to 0.87) <0.001 1.21 (1.09–1.35) <0.001
Regimen combination
 d4t/3TC+EFV 1 1 1 1
 TDF/3TC/EFV 1.06 (0.97 to 1.16) 0.220 1.24 (1.10–1.40) 0.797 1.14 (1.09 to 1.19) <0.001 0.14 (0.12–0.15) <0.001
 TDF/FTC/EFV (FDC) 0.83 (0.77 to 0.90) <0.001 1.42 (1.26–1.59) <0.001 0.83 (0.80 to 0.86) <0.001 0.017 (0.015–0.019) <0.001
Level of care
 Hospital 1 1 1 1
 CHC 1.91 (1.79 to 2.04) <0.001 2.20 (2.02–2.39) <0.001 1.27 (1.22 to 1.31) <0.001 1.14 (1.07–1.21) <0.001
 PHC 1.22 (1.14 to 1.30) <0.001 1.15 (1.05–1.25) 0.001 1.20 (1.16 to 1.25) <0.001 1.51 (1.42–1.60) <0.001

Bold p values denote statistical significance at the p≤0.05 level. Analysis adjusted for: CD4 at baseline or CD4 at ART initiation and duration on ART.

ART, antiretroviral therapy; CHC, community health centre; d4T, stavudine; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; LTFU, lost to follow-up; PHC, primary healthcare clinic; 3TC, lamivudine; TDF, tenofovir; VL, viral load.